Display options
Cite
Leppert W, Kowalski G. Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain. Onco Targets Ther. 2015;8:3621-7doi: 10.2147/OTT.S91347.
Leppert, W., & Kowalski, G. (2015). Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain. OncoTargets and therapy, 83621-7. https://doi.org/10.2147/OTT.S91347
Leppert, Wojciech, and Kowalski, Grzegorz. "Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain." OncoTargets and therapy vol. 8 (2015): 3621-7. doi: https://doi.org/10.2147/OTT.S91347
Leppert W, Kowalski G. Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain. Onco Targets Ther. 2015 Dec 04;8:3621-7. doi: 10.2147/OTT.S91347. eCollection 2015. PMID: 26675083; PMCID: PMC4675634.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 Dec 04;8:3621-7. doi: 10.2147/OTT.S91347. eCollection 2015.

Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain.

OncoTargets and therapy

Wojciech Leppert, Grzegorz Kowalski

Affiliations

  1. Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland.

PMID: 26675083 PMCID: PMC4675634 DOI: 10.2147/OTT.S91347

Abstract

BACKGROUND: Buprenorphine is often administered by the transdermal route (transdermal buprenorphine [TB]) in cancer patients with severe neuropathic pain. However, high doses of TB of 140 µg/h are rarely used.

PATIENTS AND METHODS: Three cancer patients with severe neuropathic Numeric Rating Scale (NRS) pain scores of 8-10 who were successfully treated with high doses of TB up to 140 µg/h along with other opioids and adjuvant analgesics.

RESULTS: TB was administered for a long period of follow-up (9 months to 4 years, including 34-261 days of treatment with the dose of 140 µg/h), which allowed achievement of satisfactory analgesia (NRS 3-5) and good treatment tolerance. In all three patients, TB dose was gradually titrated from 35 to 140 µg/h, and all patients used morphine at least for some time for breakthrough and background pain management along with adjuvant analgesics. Two patients continued the treatment with TB until the end of life, and one patient is still receiving the treatment.

CONCLUSION: TB at doses of up to 140 µg/h in cancer patients with severe neuropathic pain seems to be effective and safe in combination with other opioids and with adjuvant analgesics, and may significantly improve patients' quality of life. Clinical studies may explore higher than maximal 140 µg/h TB doses recommended by a manufacturer, and also in combination with other opioids and adjuvant analgesics.

Keywords: adverse effects; analgesia; cancer; neuropathic pain; transdermal buprenorphine; treatment

References

  1. Pain. 2005 Nov;118(1-2):15-22 - PubMed
  2. Curr Med Res Opin. 2011 Jun;27(6):1109-17 - PubMed
  3. Palliat Med. 2006;20 Suppl 1:s25-30 - PubMed
  4. Eur J Pain. 2005 Oct;9(5):599-611 - PubMed
  5. Case Rep Oncol. 2013 Mar 29;6(1):169-73 - PubMed
  6. Schmerz. 2009 Apr;23(2):180-6 - PubMed
  7. Lancet Oncol. 2012 Feb;13(2):e58-68 - PubMed
  8. Neurol Neurochir Pol. 2014;48(6):423-35 - PubMed
  9. Eur J Pain. 2009 Mar;13(3):219-30 - PubMed
  10. Pharmacol Rep. 2012;64(4):870-7 - PubMed
  11. Eur J Pharmacol. 2005 Jan 10;507(1-3):87-98 - PubMed
  12. Support Care Cancer. 2005 Nov;13(11):878-87 - PubMed
  13. J Pain Symptom Manage. 2005 Mar;29(3):297-326 - PubMed
  14. Eur J Pharmacol. 2004 May 10;492(1):27-34 - PubMed
  15. Clin Pharmacol Ther. 1994 May;55(5):569-80 - PubMed
  16. Support Care Cancer. 2007 Apr;15(4):441-4 - PubMed
  17. Curr Med Res Opin. 2005 Aug;21(8):1147-56 - PubMed
  18. J Pain Symptom Manage. 2006 Aug;32(2):175-9 - PubMed
  19. J Palliat Care. 2013 Summer;29(2):119-21 - PubMed
  20. Mol Pharmacol. 1993 Jul;44(1):173-9 - PubMed
  21. Pain Pract. 2008 Sep-Oct;8(5):355-61 - PubMed
  22. Expert Rev Clin Pharmacol. 2008 Nov;1(6):729-36 - PubMed
  23. Clin Ther. 2003 Jan;25(1):150-68 - PubMed
  24. Acta Clin Belg. 2013 Mar-Apr;68(2):87-91 - PubMed
  25. Cochrane Database Syst Rev. 2015 Mar 31;(3):CD009596 - PubMed
  26. Ther Clin Risk Manag. 2009 Oct;5(5):707-18 - PubMed

Publication Types